Amivantamab Efficacy and the COPERNICUS Approach: What the Data Mean for APP Practice in EGFR-Mutated Non-Small Cell Lung Cancer

Elizabeth Dennis, MSN, APRN, FNP-C, explains how overall survival data from the MARIPOSA trial changed the first-line conversation for patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer.

Elizabeth Dennis, MSN, APRN, FNP-C, describes what distinguishes the COPERNICUS study from the MARIPOSA trial in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer: a focus on treatment implementation, not only efficacy.

Elizabeth Dennis, MSN, APRN, FNP-C, reviews longer follow-up safety data from the COPERNICUS study and links the adverse events of amivantamab plus lazertinib to their mechanisms in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer.

Elizabeth Dennis, MSN, APRN, FNP-C, shares how she manages amivantamab plus lazertinib in patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer, starting with prevention on day 1.